Page last updated: 2024-10-22

amsacrine and Leukemia, Promyelocytic, Acute

amsacrine has been researched along with Leukemia, Promyelocytic, Acute in 23 studies

Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.

Leukemia, Promyelocytic, Acute: An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.

Research Excerpts

ExcerptRelevanceReference
"Thirty-nine patients with untreated acute promyelocytic leukemia (APL) were randomly allocated to receive rubidazone (zorubicin) 200 mg/m2/d, days 1 to 4 plus cytarabine (Ara C) 200 mg/m2/d, days 1 to 7 (arm A, 21 patients), or amsacrine (Amsa) 150 mg/m2/d, days 1 to 4 plus Ara C 200 mg/m2/d, days 1 to 7 (arm B, 18 patients)."9.07A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. ( Bordessoule, D; Castaigne, S; Colombat, P; Fenaux, P; Guy, H; Le Gall, E; Leblay, R; Leverger, G; Tertian, G; Tilly, H, 1991)
"Thirty-nine patients with untreated acute promyelocytic leukemia (APL) were randomly allocated to receive rubidazone (zorubicin) 200 mg/m2/d, days 1 to 4 plus cytarabine (Ara C) 200 mg/m2/d, days 1 to 7 (arm A, 21 patients), or amsacrine (Amsa) 150 mg/m2/d, days 1 to 4 plus Ara C 200 mg/m2/d, days 1 to 7 (arm B, 18 patients)."5.07A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. ( Bordessoule, D; Castaigne, S; Colombat, P; Fenaux, P; Guy, H; Le Gall, E; Leblay, R; Leverger, G; Tertian, G; Tilly, H, 1991)
"Fifty-seven adult patients with acute promyelocytic leukemia (APL) were treated between 1974 and 1984 with daunorubicin (DNR) or 4-(9-acridinylamino)methanesulfan-m-anisidide (AMSA) in combination with arabinosylcytosine (Ara-C) and 6-thioguanine (TG); they also received prophylactic heparin."5.06Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. ( Clarkson, BD; Cunningham, I; Gee, TS; Kempin, SJ; Naval, AN; Reich, LM, 1989)
"Laboratory evidence of disseminated intravascular coagulation (DIC) and/or fibrinolysis is present in the majority of patients with acute promyelocytic leukemia (APL)."2.68Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. ( Escudier, SM; Estey, EH; Kantarjian, HM, 1996)

Research

Studies (23)

TimeframeStudies, this research(%)All Research%
pre-19905 (21.74)18.7374
1990's15 (65.22)18.2507
2000's2 (8.70)29.6817
2010's0 (0.00)24.3611
2020's1 (4.35)2.80

Authors

AuthorsStudies
Abdelgawad, MA1
Mohamed, FEA1
Lamie, PF1
Bukhari, SNA1
Al-Sanea, MM1
Musa, A1
Elmowafy, M1
Nayl, AA1
Karam Farag, A1
Ali, SM1
Shaker, ME1
Omar, HA1
Abdelhameid, MK1
Kandeel, MM1
Fouillard, L1
Labopin, M1
Meloni, G2
Polge, E1
Gorin, NC1
Frassoni, F1
Capria, S1
Latagliata, R1
Avvisati, G1
Breccia, M1
Cimino, G1
Diverio, D1
Petti, MC1
Solary, E1
Bertrand, R1
Kohn, KW1
Pommier, Y1
Ganapathi, R1
Zwelling, L1
Constantinou, A2
Ford, J1
Grabowski, D1
Boege, F2
Gieseler, F2
Biersack, H2
Meyer, P2
Ghaddar, HM1
Pierce, S1
Kantarjian, HM2
Freireich, EJ1
Keating, MJ1
Estey, EH2
Escudier, SM1
Thomas, X1
Fiere, D1
Archimbaud, E1
Wan, Y1
Wu, D1
Hotz, MA1
Del Bino, G1
Lassota, P1
Traganos, F1
Darzynkiewicz, Z1
Kaufmann, SH1
Arlin, ZA1
Feldman, EJ1
Cook, P1
Ahmed, T1
Mittelman, A1
Chun, HG1
Puccio, C1
Helson, L1
Fenaux, P1
Tertian, G1
Castaigne, S1
Tilly, H1
Leverger, G1
Guy, H1
Bordessoule, D1
Leblay, R1
Le Gall, E1
Colombat, P1
Zwelling, LA3
Mayes, J3
Hinds, M3
Chan, D3
Altschuler, E1
Carroll, B1
Parker, E2
Deisseroth, K1
Radcliffe, A2
Seligman, M1
Gorsky, LD1
Morin, MJ1
Ling, YH1
Andersson, BS1
Nelson, JA1
Henning-Chubb, C1
Huberman, E1
Sie, KL1
Silberman, L1
Beran, M1
Blick, M2
Mukaiyama, T1
Ogawa, M1
Horikoshi, N1
Inoue, K1
Fukutani, H1
Tabata, M1
Hirano, A1
Mizunuma, N1
Itami, S1
Silberman, LE1
Cunningham, I1
Gee, TS1
Reich, LM1
Kempin, SJ1
Naval, AN1
Clarkson, BD1

Trials

5 trials available for amsacrine and Leukemia, Promyelocytic, Acute

ArticleYear
BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results.
    Bone marrow transplantation, 2005, Volume: 36, Issue:1

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

2005
Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
    Leukemia & lymphoma, 1996, Volume: 22, Issue:1-2

    Topics: Acute Disease; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Co

1996
Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid.
    Leukemia & lymphoma, 1996, Volume: 20, Issue:5-6

    Topics: Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemot

1996
A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:9

    Topics: Adolescent; Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Prot

1991
Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital.
    Blood, 1989, Volume: 73, Issue:5

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun

1989

Other Studies

18 other studies available for amsacrine and Leukemia, Promyelocytic, Acute

ArticleYear
Design, synthesis, and biological evaluation of novel pyrido-dipyrimidines as dual topoisomerase II/FLT3 inhibitors in leukemia cells.
    Bioorganic chemistry, 2022, Volume: 122

    Topics: Amsacrine; Antineoplastic Agents; Apoptosis; Cell Proliferation; DNA Topoisomerases, Type II; fms-Li

2022
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
    Haematologica, 2004, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmus

2004
Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.
    Blood, 1993, Mar-01, Volume: 81, Issue:5

    Topics: Amsacrine; Apoptosis; Camptothecin; Cell Differentiation; DNA; DNA Damage; Etoposide; Humans; Leukem

1993
Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells.
    Biochemical and biophysical research communications, 1993, May-14, Volume: 192, Issue:3

    Topics: Amsacrine; Autoradiography; DNA Topoisomerases, Type II; Drug Resistance; Electrophoresis, Polyacryl

1993
Different functional states of topoisomerase II can be discriminated by orthovanadate sensitivity in multi-drug resistant human leukemic cells.
    Leukemia & lymphoma, 1993, Volume: 9, Issue:4-5

    Topics: Adenosine Triphosphate; Allosteric Site; Amsacrine; Chromatography, Ion Exchange; Clone Cells; DNA T

1993
Influence of increased body mass index on drug toxicity in patients with acute promyelocytic leukemia.
    Leukemia, 1998, Volume: 12, Issue:9

    Topics: Adult; Aged; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols;

1998
[Studies on programmed cell death induced by amsacrine and expression of bcl-2 in leukemia cell lines].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1997, Volume: 19, Issue:5

    Topics: Amsacrine; Antineoplastic Agents; Apoptosis; Gene Expression; Genes, bcl-2; HL-60 Cells; Humans; Leu

1997
The measurement of nuclear topoisomerase II inhibition in vitro: a possible tool for detecting resistance on a subcellular level in haematopoietic malignancies.
    European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, 1992, Volume: 30, Issue:2

    Topics: Amsacrine; Antineoplastic Agents; Cell Nucleus; Drug Resistance; Etoposide; Humans; In Vitro Techniq

1992
Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells.
    Cancer research, 1992, Mar-15, Volume: 52, Issue:6

    Topics: Alkenes; Amsacrine; Antibiotics, Antineoplastic; Cell Cycle; DNA, Neoplasm; Humans; Leukemia, Lympho

1992
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
    Cancer research, 1991, Feb-15, Volume: 51, Issue:4

    Topics: Amsacrine; Aphidicolin; Blotting, Western; Camptothecin; Colony-Forming Units Assay; Cycloheximide;

1991
Amsacrine retains a special role supporting Food and Drug Administration approval.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:1

    Topics: Amsacrine; Humans; Leukemia, Promyelocytic, Acute; United States; United States Food and Drug Admini

1992
Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Biochemistry, 1991, Apr-23, Volume: 30, Issue:16

    Topics: Amsacrine; Antineoplastic Agents; Cell Line; Cell Nucleus; Cell Survival; DNA Topoisomerases, Type I

1991
Microsomal activation and increased production of 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide (m-AMSA)-dependent, topoisomerase-associated DNA lesions in nuclei from human HL-60 leukemia cells.
    Biochemical pharmacology, 1990, May-01, Volume: 39, Issue:9

    Topics: Amsacrine; Cell Nucleus; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Humans; Leukemia, P

1990
DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Cancer biochemistry biophysics, 1990, Volume: 11, Issue:1

    Topics: Amsacrine; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; DNA Damage; DNA Topoisome

1990
Novobiocin- and phorbol-12-myristate-13-acetate-induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity.
    Cancer research, 1989, Mar-01, Volume: 49, Issue:5

    Topics: Amsacrine; Cell Differentiation; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Humans; Le

1989
Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    The Journal of biological chemistry, 1989, Oct-05, Volume: 264, Issue:28

    Topics: Adenosine Triphosphate; Amsacrine; Blotting, Northern; Blotting, Southern; Cell Line; Cell Nucleus;

1989
[4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun

1989
Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
    Cancer research, 1988, Dec-01, Volume: 48, Issue:23

    Topics: Amsacrine; Chromatin; DNA; DNA Damage; DNA Topoisomerases, Type II; Etoposide; Humans; Leukemia, Pro

1988